INTEGRATED BIOPHARMA INC (OTC:INBP) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on October 28, 2026.
At publication ·
INTEGRATED BIOPHARMA INC (OTC:INBP) · proxy filed
At a glance
INTEGRATED BIOPHARMA INC (OTC:INBP) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on October 28, 2026.
The Consumer Defensive company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
INTEGRATED BIOPHARMA INC's stock currently trades at $0.17 with a market capitalization of $9.6M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing INTEGRATED BIOPHARMA INC's filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for INTEGRATED BIOPHARMA INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View INBP Stock Page
Browse all filings on our INBP SEC filings page.
Public companies like INTEGRATED BIOPHARMA INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Keep reading
Current market data
OTC · INBP
$0.17
Up: +$0.01 · +5.21%
Live quote updated
